Not so long ago, Kannapolis, North Carolina was a town built around the manufacture of towels. Today, the old Cannon Textile Mill is home to a medical research campus seeking to integrate self-reported data and electronic health records with biobanked tissue samples and the latest omics tools. Funded by real estate developer and Dole Foods owner David H. Murdock, the Kannapolis-based M.U.R.D.O.C.K. (for Measurement to Understand the Reclassification of Disease Of Cabarrus / Kannapolis) study has been called the Framingham study of the molecular age a reference to the famed Massachusetts heart study begun in 1948. Simon Gregory, an Associate Professor of Medicine at Duke and director of the Genomics Core at the Kannapolis campus, has devoted his last seven years working with MURDOCK investigators to study candidate genes related to cardiovascular disease, autism, and developmental disorders. But Gregory has a special interest in applying the resources in Kannapolis to understand multiple sclerosis (MS). Through our parallel studies, we hope to identify new genes or pathways that could become novel drug targets, he said. This may help prevent the initiation of the disease itself or at least slow its progression. That could mean better medicines for the approximately two million … Continue reading →

Seoul (The Korea Herald/ANN) - Yuhan Corporation, a Seoul-based pharmaceutical company, said Tuesday that it had launched a genetic information analysis service that tracks down personal genetic risks for certain diseases and disorders. In a joint venture with Theragen Etex, a local biotech firm specializing in genetic code analysis, Yuhan introduced "Hello Gene" that tests personal genetic information with just a few drops of blood, the company said. The service interprets ones genetic information within a week or two and predicts what kind of diseases or disorders the person is vulnerable to. It will also design a new lifestyle tailored to the individuals genetic and phenotypic information, the company added. "We are experiencing a paradigm shift to (new) medical technology and service that offers ways to prevent diseases, long before they start treating them," a Yuhan official told reporters in Seoul. The genetic information technology will open the data-driven medicine of tomorrow that improves treatment effectiveness and minimizes the side effects of drugs, he added. The Korean drug maker plans to expand R&D investment on developing personalized medicine such as new drugs tailored to ones genetic information and technological devices that would offer more accurate diagnosis to patients. Yuhan pinned … Continue reading →

25th January 2013 -- Again no fatigue while eating in restaurant -- part 11 I have a Spinal Muscular Atrophy from birth, it's in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video. By: Kina Diamond … Continue reading →

Biotech Showcase 2012_ReNeuron ReNeuron is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead therapeutic candidate is our ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This treatment is currently in clinical development. We are also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side effect of diabetes, and blindness-causing diseases of the retina. http://www.reneuron.com View ReNeuron's Alliance for Regenerative Medicine member profile at alliancerm.org By: AllianceRegenMed … Continue reading →

Public release date: 29-Jan-2013 [ | E-mail | Share ] Contact: Sally Stewart sally.stewart@cshs.org 310-248-6566 Cedars-Sinai Medical Center LOS ANGELES (Jan. 30, 2012) Injecting specialized cardiac stem cells into a patient's heart rebuilds healthy tissue after a heart attack, but where do the new cells come from and how are they transformed into functional muscle? Researchers at the Cedars-Sinai Heart Institute, whose clinical trial results in 2012 demonstrated that stem cell therapy reduces scarring and regenerates healthy tissue after a heart attack, now have found that the stem cell technique boosts production of existing adult heart cells (cardiomyocytes) and spurs recruitment of existing stem cells that mature into heart cells. The findings, from a laboratory animal study, are published in EMBO Molecular Medicine online. "We're finding that the effect of stem cell therapy is indirect. It stimulates proliferation of dormant surviving host heart tissue, and it attracts stem cells already in the heart. The resultant new heart muscle is functional and durable, but the transplanted stem cells themselves do not last long," said Eduardo Marbn, MD, PhD, director of the Heart Institute. Marbn, the article's senior author, invented the experimental stem cell procedures and technology tested in humans. Consistent with … Continue reading →

Jan. 29, 2013 Injecting specialized cardiac stem cells into a patient's heart rebuilds healthy tissue after a heart attack, but where do the new cells come from and how are they transformed into functional muscle? Researchers at the Cedars-Sinai Heart Institute, whose clinical trial results in 2012 demonstrated that stem cell therapy reduces scarring and regenerates healthy tissue after a heart attack, now have found that the stem cell technique boosts production of existing adult heart cells (cardiomyocytes) and spurs recruitment of existing stem cells that mature into heart cells. The findings, from a laboratory animal study, are published in EMBO Molecular Medicine online. "We're finding that the effect of stem cell therapy is indirect. It stimulates proliferation of dormant surviving host heart tissue, and it attracts stem cells already in the heart. The resultant new heart muscle is functional and durable, but the transplanted stem cells themselves do not last long," said Eduardo Marbn, MD, PhD, director of the Heart Institute. Marbn, the article's senior author, invented the experimental stem cell procedures and technology tested in humans. Consistent with previous studies, the researchers found that the heart's native stem cells are not responsible for the normal replenishment of lost … Continue reading →

Alexandra Glucksmann What Is Nanomedicine By: careergirls … Continue reading →